Rapport Therapeutics (NASDAQ:RAPP) Stock: Insider Paul Silva Acquires 3,680 Shares

Posted by George Bondi on Oct 24th, 2026

Rapport Therapeutics, Inc. (NASDAQ:RAPP – Get Free Report) Director Paul Silva purchased 3,680 shares of Rapport Therapeutics stock in a transaction that occurred on Thursday, October 22nd. The stock was acquired at an average price of $27.07 per share, with a total value of $99,617.60. Following the transaction, the director owned 3,680 shares in the company, valued at $99,617.60. The trade was a ∞ increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink.

Rapport Therapeutics Trading Down 2.3%

Shares of NASDAQ:RAPP opened at $25.93 on Friday. Rapport Therapeutics, Inc. has a 1-year low of $23.75 and a 1-year high of $52.93. The firm has a fifty day moving average price of $39.01 and a 200 day moving average price of $38.93.

Rapport Therapeutics (NASDAQ:RAPP – Get Free Report) last posted its quarterly earnings data on Wednesday, August 5th. The company reported ($1.19) EPS for the quarter, missing analysts’ consensus estimates of ($1.12) by ($0.07). On average, research analysts forecast that Rapport Therapeutics, Inc. will post -4.08 EPS for the current fiscal year.

Trending Headlines about Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

Positive Sentiment: RAP-219 met both Phase 2 endpoints in bipolar mania. The drug delivered statistically significant placebo-adjusted improvements in mania scores, and Rapport plans to advance it into Phase 3. Success could expand RAP-219’s opportunity beyond epilepsy and materially increase the company’s pipeline value. Rapport Therapeutics Phase 2 results
Positive Sentiment: Analysts remain optimistic and raised price targets. JonesTrading lifted its target to $82, BTIG to $89 and Raymond James to $86, while HC Wainwright maintained a Buy rating. The reported consensus target of approximately $68.36 implies substantial upside from recent levels. Rapport Therapeutics analyst price target
Positive Sentiment: Multiple insiders bought shares on the open market. CFO Troy Ignelzi purchased 5,500 shares, while directors Steven Paul, John Maraganore, Wendy Young, Paul Silva and Ramiro Sanchez also bought shares. The purchases totaled roughly $1.8 million based on the disclosed transactions and may signal management confidence following the clinical update. Rapport Therapeutics insider buying
Neutral Sentiment: An analysis suggested Rapport could be significantly below estimated fair value following the Phase 2 results, but that valuation depends on successful Phase 3 development, regulatory approval and eventual commercialization.
Negative Sentiment: Investors may have viewed the clinical win as less decisive than hoped. Reports indicated that some portions of the data only narrowly met expectations, potentially prompting profit-taking after the initial rally. Rapport bipolar mania data analysis
Negative Sentiment: Rapport remains an unprofitable clinical-stage biotechnology company. Its latest quarterly loss missed analyst expectations, and analysts forecast a full-year loss of approximately $4.09 per share. CEO Abraham Ceesay also sold 2,210 shares, a relatively small reduction of 0.49% in his holdings, which contrasts with the broader insider buying. SEC CEO ownership filing

Analyst Ratings Changes

A number of research firms recently issued reports on RAPP. Weiss Ratings reissued a “sell (d-)” rating on shares of Rapport Therapeutics in a report on Thursday, October 15th. Wolfe Research began coverage on Rapport Therapeutics in a research note on Thursday, October 15th. They set an “outperform” rating and a $50.00 price objective for the company. Citigroup reaffirmed an “outperform” rating on shares of Rapport Therapeutics in a research note on Tuesday. Wells Fargo & Company decreased their price objective on Rapport Therapeutics from $51.00 to $50.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, TD Cowen reiterated a “buy” rating on shares of Rapport Therapeutics in a research note on Tuesday. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $68.36.

View Our Latest Stock Analysis on Rapport Therapeutics

Institutional Investors Weigh In On Rapport Therapeutics

Institutional investors have recently added to or reduced their stakes in the business. Sterling Capital Management LLC lifted its holdings in Rapport Therapeutics by 597.9% in the third quarter. Sterling Capital Management LLC now owns 984 shares of the company’s stock valued at $33,000 after acquiring an additional 843 shares during the period. Engineers Gate Manager LP acquired a new position in shares of Rapport Therapeutics during the 2nd quarter worth $888,000. Wellington Management Group LLP grew its stake in shares of Rapport Therapeutics by 11.2% during the 2nd quarter. Wellington Management Group LLP now owns 86,988 shares of the company’s stock worth $3,625,000 after purchasing an additional 8,757 shares during the period. Artia Global Partners LP purchased a new position in shares of Rapport Therapeutics in the 2nd quarter valued at about $5,772,000. Finally, Bank of America Corp DE purchased a new position in shares of Rapport Therapeutics in the 2nd quarter valued at about $3,170,000.

About Rapport Therapeutics

(Get Free Report)

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision medicines for central nervous system disorders. The company’s approach is designed to selectively target receptor-associated proteins that regulate synaptic receptors, with the goal of improving therapeutic selectivity and reducing the side effects associated with broader-acting neurological medicines.

Rapport’s lead product candidate, RAP-219, is an orally administered small molecule being developed for neurological conditions, including focal epilepsy.